Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Shionogi Spurns Europe, Places Bets On Asia For Global Expansion - Bio Expo Japan

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Shionogi, set on global expansion, has rejected initial plans to expand into Europe, instead turning to emerging markets in Asia

You may also be interested in...



Japanese Earnings Roundup: Shionogi Rebounds From U.S. Acquisition Woes With C&O Pharmaceutical For China; Astellas Ponders Mirabegron's Reproductive Warning

TOKYO - Shionogi & Co. Ltd. will expand its operations in China with the acquisition of C&O Pharmaceutical Technology Ltd., following through on a promise from its midterm plan to push into Asia to mitigate the 2016 patent loss of blockbuster Crestor (rosuvastatin)

Japanese Earnings Roundup: Shionogi Rebounds From U.S. Acquisition Woes With C&O Pharmaceutical For China; Astellas Ponders Mirabegron's Reproductive Warning

TOKYO - Shionogi & Co. Ltd. will expand its operations in China with the acquisition of C&O Pharmaceutical Technology Ltd., following through on a promise from its midterm plan to push into Asia to mitigate the 2016 patent loss of blockbuster Crestor (rosuvastatin)

Japan Earnings Roundup: Shinogi & Co.'s China Deal And Astellas Pharma Inc.'s Label Woes

Shionogi rebounds from U.S. acquisition woes with C&O Pharmaceutical for China; Astellas ponders Mirabegron's reproductive warning.

Related Content

Latest News
UsernamePublicRestriction

Register

SC075311

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel